Trial Profile
An Open-Label, Multiple-Dose, Randomized, Crossover Study In Healthy Volunteers To Investigate The Pharmacokinetics Of Three Dose Strengths Of Pregabalin Controlled Release Formulations Administered Following An Evening Meal As Compared To The Immediate Release Formulation.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Jan 2021
Price :
$35
*
At a glance
- Drugs Pregabalin (Primary) ; Pregabalin (Primary)
- Indications Fibromyalgia; Generalised anxiety disorder; Neuropathic pain; Partial epilepsies; Postherpetic neuralgia; Tonic-clonic epilepsy
- Focus Pharmacokinetics
- Sponsors Pfizer
- 30 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Dec 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 10 Nov 2009 New trial record